These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3048225)

  • 1. The effects of acute scopolamine in geriatric depression.
    Newhouse PA; Sunderland T; Tariot PN; Weingartner H; Thompson K; Mellow AM; Cohen RM; Murphy DL
    Arch Gen Psychiatry; 1988 Oct; 45(10):906-12. PubMed ID: 3048225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic sensitivity in patients with dementia of the Alzheimer type and age-matched controls. A dose-response study.
    Sunderland T; Tariot PN; Cohen RM; Weingartner H; Mueller EA; Murphy DL
    Arch Gen Psychiatry; 1987 May; 44(5):418-26. PubMed ID: 3579494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scopolamine challenges in Alzheimer's disease.
    Sunderland T; Tariot P; Murphy DL; Weingartner H; Mueller EA; Cohen RM
    Psychopharmacology (Berl); 1985; 87(2):247-9. PubMed ID: 3931154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lorazepam and scopolamine: A single-dose comparison of effects on human memory and attentional processes.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2003 Feb; 11(1):56-72. PubMed ID: 12622344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood.
    Curran HV; Schifano F; Lader M
    Psychopharmacology (Berl); 1991; 103(1):83-90. PubMed ID: 2006245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers.
    Dukoff R; Wilkinson CW; Lasser R; Friz J; Conway A; Bahro M; Peskind ER; Sunderland T
    Biol Psychiatry; 1999 Jul; 46(2):189-95. PubMed ID: 10418693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of scopolamine and lorazepam on working memory maintenance versus manipulation processes.
    Mintzer MZ; Griffiths RR
    Cogn Affect Behav Neurosci; 2007 Jun; 7(2):120-9. PubMed ID: 17672383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine but not lorazepam modulates face repetition priming: a psychopharmacological fMRI study.
    Thiel CM; Henson RN; Dolan RJ
    Neuropsychopharmacology; 2002 Aug; 27(2):282-92. PubMed ID: 12093602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (Lemon balm) with human CNS nicotinic and muscarinic receptor-binding properties.
    Kennedy DO; Wake G; Savelev S; Tildesley NT; Perry EK; Wesnes KA; Scholey AB
    Neuropsychopharmacology; 2003 Oct; 28(10):1871-81. PubMed ID: 12888775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls.
    Sunderland T; Weingartner H; Cohen RM; Tariot PN; Newhouse PA; Thompson KE; Lawlor BA; Mueller EA
    Psychopharmacology (Berl); 1989; 99(1):129-33. PubMed ID: 2506598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple-dose arecoline infusions in Alzheimer's disease.
    Tariot PN; Cohen RM; Welkowitz JA; Sunderland T; Newhouse PA; Murphy DL; Weingartner H
    Arch Gen Psychiatry; 1988 Oct; 45(10):901-5. PubMed ID: 3048224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scopolamine induces impairments in the recognition of human facial expressions of anger and disgust.
    Kamboj SK; Curran HV
    Psychopharmacology (Berl); 2006 May; 185(4):529-35. PubMed ID: 16555061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed.
    Flicker C; Serby M; Ferris SH
    Psychopharmacology (Berl); 1990; 100(2):243-50. PubMed ID: 2305013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scopolamine and lorazepam exert different patterns of effects in a test battery assessing stages of information processing.
    Duka T; Redemann B; Voet B
    Psychopharmacology (Berl); 1995 Jun; 119(3):315-24. PubMed ID: 7675968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen replacement attenuates effects of scopolamine and lorazepam on memory acquisition and retention.
    Gibbs RB; Burke AM; Johnson DA
    Horm Behav; 1998 Oct; 34(2):112-25. PubMed ID: 9799622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity to scopolamine in the elderly.
    Flicker C; Ferris SH; Serby M
    Psychopharmacology (Berl); 1992; 107(2-3):437-41. PubMed ID: 1615141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model.
    Molchan SE; Martinez RA; Hill JL; Weingartner HJ; Thompson K; Vitiello B; Sunderland T
    Brain Res Brain Res Rev; 1992; 17(3):215-26. PubMed ID: 1467811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-related decline in central cholinergic function demonstrated with scopolamine.
    Tariot PN; Patel SV; Cox C; Henderson RE
    Psychopharmacology (Berl); 1996 May; 125(1):50-6. PubMed ID: 8724448
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.